We have located links that may give you full text access.
Journal Article
Review
Comparison between the efficacy of combination therapy and monotherapy in connective tissue disease associated pulmonary arterial hypertension: a systematic review and meta-analysis.
Clinical and Experimental Rheumatology 2018 June 15
OBJECTIVES: Although the efficacy of combined treatment targeting pulmonary arterial hypertension (PAH) has been suggested to be preferable, the comparative efficacy of combination therapy versus monotherapy in connective tissue disease (CTD)-associated PAH (CTD-PAH) remains undetermined. We performed a meta-analysis regarding this topic.
METHODS: The Cochrane Library, MEDLINE, PubMed, and EMBASE databases were searched for randomised controlled trials (RCTs) that directly compared the efficacies of combination therapy and monotherapy targeting PAH in patients with CTD-PAH. The risk of the clinical worsening of PAH and changes in 6-minute walk distance (6MWD) were evaluated. The Mantel-Hansel method was used to pool the results with a random-effects model.
RESULTS: Six RCTs with 963 patients were included. The results of the meta-analysis showed that combination therapy significantly reduced the risk of clinical worsening events by 27% (pooled relative risk of 0.73, 95% confidence interval (CI) [0.60-0.89], p=0.002) with no significant heterogeneity (I2=13%, Ph=0.33) and tended to increase 6MWD by 21.38 m (95% CI [-20.38 to 63.14]; p=0.32; I2=58, Ph=0.09). No significant heterogeneity was indicated with funnel plots.
CONCLUSIONS: Combination therapy targeting PAH may confer preferable therapeutic efficacy compared with monotherapy in patients with CTD-PAH as evidenced by a more remarkable reduction in the risk of clinical worsening and a probable improvement of exercise capacity in these patients.
METHODS: The Cochrane Library, MEDLINE, PubMed, and EMBASE databases were searched for randomised controlled trials (RCTs) that directly compared the efficacies of combination therapy and monotherapy targeting PAH in patients with CTD-PAH. The risk of the clinical worsening of PAH and changes in 6-minute walk distance (6MWD) were evaluated. The Mantel-Hansel method was used to pool the results with a random-effects model.
RESULTS: Six RCTs with 963 patients were included. The results of the meta-analysis showed that combination therapy significantly reduced the risk of clinical worsening events by 27% (pooled relative risk of 0.73, 95% confidence interval (CI) [0.60-0.89], p=0.002) with no significant heterogeneity (I2=13%, Ph=0.33) and tended to increase 6MWD by 21.38 m (95% CI [-20.38 to 63.14]; p=0.32; I2=58, Ph=0.09). No significant heterogeneity was indicated with funnel plots.
CONCLUSIONS: Combination therapy targeting PAH may confer preferable therapeutic efficacy compared with monotherapy in patients with CTD-PAH as evidenced by a more remarkable reduction in the risk of clinical worsening and a probable improvement of exercise capacity in these patients.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
Perioperative echocardiographic strain analysis: what anesthesiologists should know.Canadian Journal of Anaesthesia 2024 April 11
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app